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Abstract
Background: Bacterial colonisation in chronic obstructive pulmonary disease (COPD) contributes to airway 
inflammation and modulates exacerbations. We assessed risk factors for bacterial colonisation in COPD.
Methods: Patients with stable COPD consecutively recruited over 1 year gave consent to provide a sputum sample for 
microbiologic analysis. Bronchial colonisation by potentially pathogenic microorganisms (PPMs) was defined as the 
isolation of PPMs at concentrations of ≥102 colony-forming units (CFU)/mL on quantitative bacterial culture. Colonised 
patients were divided into high (>105 CFU/mL) or low (<105 CFU/mL) bacterial load.
Results: A total of 119 patients (92.5% men, mean age 68 years, mean forced expiratory volume in one second [FEV1] 
[% predicted] 46.4%) were evaluated. Bacterial colonisation was demonstrated in 58 (48.7%) patients. Patients with and 
without bacterial colonisation showed significant differences in smoking history, cough, dyspnoea, COPD 
exacerbations and hospitalisations in the previous year, and sputum colour. Thirty-six patients (62% of those colonised) 
had a high bacterial load. More than 80% of the sputum samples with a dark yellow or greenish colour yielded PPMs in 
culture. In contrast, only 5.9% of white and 44.7% of light yellow sputum samples were positive (P < 0.001). Multivariate 
analysis showed an increased degree of dyspnoea (odds ratio [OR] = 2.63, 95% confidence interval [CI] 1.53-5.09, P = 
0.004) and a darker sputum colour (OR = 4.11, 95% CI 2.30-7.29, P < 0.001) as factors associated with the presence of 
PPMs in sputum.
Conclusions: Almost half of our population of ambulatory moderate to very severe COPD patients were colonised 
with PPMs. Patients colonised present more severe dyspnoea, and a darker colour of sputum allows identification of 
individuals more likely to be colonised.
Background
Exacerbations are the main cost driver in chronic
obstructive pulmonary disease (COPD), have a negative
impact on the clinical course of the patients and are asso-
ciated with increased mortality [1-3]. Around 70% of
exacerbations are infectious in nature, either bacterial,
viral or mixed [4-7]. It has been shown that airway bacte-
rial load in the stable state contributes to airway inflam-
mation and modulates the character and frequency of
exacerbations [8,9]. There is also evidence that bronchial
colonisation influences the decline in lung function over
time [10]. Different studies in which respiratory samples
were obtained by the protected specimen brush (PSB)
technique have shown a high prevalence of bronchial col-
onisation in COPD patients [5,11,12]. However, the prac-
tice of bronchoscopy to assess bronchial colonisation in
routine clinical practice is not feasible and data that sup-
port the use of sputum samples to identify patients colo-
nised by potentially pathogenic microorganisms (PPMs)
are required.
Consequently, a cross-sectional study was designed to
assess the frequency of bronchial bacterial colonisation
using sputum samples and to identify risk factors for col-
onisation in stable ambulatory patients with COPD. The
* Correspondence: marcm@separ.es
1 Fundació Clínic. Institut D'Investigacions Biomèdiques August Pi i Sunyer 
(IDIBAPS). Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
Full list of author information is available at the end of the articleMiravitlles et al. Respiratory Research 2010, 11:58
http://respiratory-research.com/content/11/1/58
Page 2 of 9
clinical characteristics of patients colonised and non-col-
o n i s e d  w i t h  P P M s  w e r e  c o m p a r e d  a s  w e r e  t h o s e  o f
patients with low and high bacterial loads in sputum sam-
ples.
Methods
A cross-sectional study was carried out to assess clinical
characteristics associated with bronchial colonisation in
stable ambulatory COPD patients. These patients were
visited at the outpatient respiratory clinics of two acute-
care tertiary hospitals in Barcelona, Spain and were con-
secutively recruited over one year. After completing the
collection of data for this study, patients with bronchial
colonisation were included in a randomised trial of anti-
biotic treatment the results of which have been reported
elsewhere [13]. The protocol was approved by the institu-
tional review board and all patients gave written
informed consent.
Study population
Eligible patients were adults over 40 years of age, smokers
o r  e x - s m o k e r s  o f  a t  l e a s t  1 0  p a c k - y e a r s ,  w i t h  s t a b l e
COPD, defined as a post-bronchodilator forced expira-
tory volume in one second (FEV1)/forced vital capacity
(FVC) ratio of <70%. A FEV1 of <60% of the predicted
value higher than 0.70 litres and a negative bronchodila-
tor test (increase in FEV1 <200 mL and <12% of baseline)
was required for inclusion in the study as was a history of
at least one documented exacerbation in the previous
year. Clinical stability was defined by the attending physi-
cian on clinical grounds based on the absence of symp-
toms of exacerbation and use of any oral or systemic
antibiotics or a course of oral corticosteroids in the 6
weeks prior to inclusion.
The exclusion criteria were the following: (1) previous
diagnosis of bronchial asthma, bronchiectasis demon-
strated by a chest X-ray or computed tomography (CT)
scan, or other relevant pulmonary diseases apart from
COPD; (2) chronic treatment with oral corticosteroids at
any dose; (3) formal contraindication for sputum induc-
tion or impossibility to obtain a valid sputum sample for
analysis; and (4) participation in another clinical study
concurrently or within the previous 3 months.
Study procedures
At the time of inclusion in the study, the investigator veri-
fied that the patient met the eligibility criteria and details
of medical history were recorded. Information regarding
comorbidities, particularly cardiovascular diseases, dia-
betes and liver or renal failure was collected. A forced
spirometry was performed following criteria of the Span-
ish Society of Pneumology and Thoracic Surgery [14] and
sputum samples were obtained. Patients unable to pro-
duce sputum were susceptible to reassessment for airway
colonisation at least one month after the initial investiga-
tion for a maximum of three consecutive visits.
Microbiological sputum study
A sputum sample was obtained and processed within 60
minutes on the day of the visit according to standard
methods [13,15,16]. Patients who did not produce spu-
tum spontaneously underwent sputum induction. In
brief, patients were pretreated with an inhaled β2-agonist
ten minutes before the nebulisation of isotonic saline
(0.9%) with an ultrasonic nebuliser (Ultraneb2000, DeVil-
biss Healthcare Inc., Somerset, PA, USA), that was fol-
lowed by increasing concentrations of hypertonic saline
(3%, 4% and 5%), for 7 min with each concentration. After
every induction, the patient attempted to obtain a spu-
tum sample by coughing, and the nebulisation procedure
was stopped when the sputum volume collected was 1
mL or more [17]. In current smokers, sputum induction
was performed after at least 6 hours of tobacco absti-
nence. The purulence of sputum was graded in a scale
from 1 to 5 according to the colour from white -1- to
greenish -5-, always by the same researcher at each cen-
tre. The sample was weighed and processed with a 4-fold
volume of dithiothreitol (Sputasol, Oxoid Ltd., Hants,
UK) and was cultured. Sputum samples were serially
diluted and plated on chocolate agar enriched, chocolate
agar with bacitracin, Haemophilus-selective agar, blood
agar, and McConkey agar. Plates were incubated for 24-48
hours at 37°C and in 5% CO2 atmosphere. Microorgan-
isms were identified by colony morphology, Gram stain-
ing and specific culture conditions (e.g., requirements for
factors for growth, presence of oxidase and catalase, por-
phyrin synthesis). Cultures were considered positive for
bronchial colonisation if microorganisms considered as
PPMs such as Haemophilus influenzae, Haemophilus
parainfluenzae, Streptococcus pneumoniae, Moraxella
catarrhalis, Pseudomonas aeruginosa, enterobacteria
and/or Staphylococcus aureus were grown at loads of at
least 100 colony-forming units (CFU)/mL according to
previously defined criteria [18,19]. Colonised patients
were then divided into high (>105 CFU/mL) or low (≤105
CFU/mL) bacterial load according to previous studies
[4,8].
Sputum concentrations of pro-inflammatory cytokines,
including interleukin-1 (IL-1), interleukin-6 (IL-6), inter-
leukin-8 (IL-8), and tumour necrosis factor-alpha (TNF-
alpha) were measured using quantitative sandwich
immunoassay techniques in processed supernatants as
previously described [20].
Statistical analysis
Variables were presented as mean values and standard
deviations, those not following a normal distribution
were presented as median and interquartile range (IQR,Miravitlles et al. Respiratory Research 2010, 11:58
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25th-75th percentile). Categorical variables were com-
pared with the chi-square test and continuous variables
with the Student's t  test or the Mann-Whitney U test
when data departed from normality. Following univariate
analysis, variables were included in two stepwise logistic
regression models constructed as exploratory analysis to
identify independent risk factors for bronchial colonisa-
tion and factors significantly associated with high bacte-
rial load as opposed to low bacterial load and sterile
sputum cultures. The variables included in the models
were: age, gender, active versus ex-smoker, pack-years of
smoking, FEV1 (% predicted), degree of dyspnoea, colour
of sputum, cardiovascular comorbidity and number of
exacerbations and hospitalisations the previous year.
Bilateral two-tailed hypotheses were formulated and 95%
confidence intervals (CI) were calculated. Statistical sig-
nificance was set at P < 0.05.
Results
A total of 119 patients (92.5% men) with a mean (stan-
dard deviation, SD) age of 68.1 (9.1) years were studied.
The clinical characteristics of these patients are reported
in Table 1. Induction of sputum was necessary to obtain a
valid sputum sample in only 5 cases (3 in one centre and 2
in the other). Bacterial colonisation was demonstrated in
58 (48.7%) patients, 2 in samples obtained by sputum
induction. Results of sputum microbiology are shown in
Table 2. Colonisation by a single PPM was recorded in 50
patients. Eight subjects yielded more than one PPM in
their sputum. Haemophilus influenzae and H. parainflu-
enzae made up 72% of all bacterial isolates.
There were significant differences in cigarette con-
sumption, cough, dyspnoea, comorbidities, COPD exac-
erbations and hospitalisations in the previous year, and
sputum colour between patients with and without bacte-
rial colonisation (Table 3).
The distribution of colonised patients according to spu-
tum colour is presented in Figure 1. Samples with colour
1 (white) were predominantly sterile, whereas in the sam-
ples with colours 3 to 5 (yellow to greenish) the preva-
lence of colonisation was higher than 80%. Colour
number two (light yellow) was not discriminative
between colonised and non-colonised.
When colonised patients were divided according to
bacterial load, 36 patients had a high bacterial load (>105
CFU/mL) and the remaining 22 had a low bacterial load
(≤105 CFU/mL). The characteristics of colonised patients
with a high bacterial load (n = 36) were compared with a
group formed by non-colonised patients (n = 61) and
those with a low bacterial load (n = 22) considered
together (n = 83). Statistically significant differences
between the two groups in smoking (pack-years), cough,
grade of dyspnoea, hospitalisations in the previous year
and sputum colour persisted when patients with high
bacterial loads were compared with the remaining
Table 1: Clinical characteristics of the study population
Data Frequency
Subjects, no. 119
Sex, men, no. (%) 112 (92.5)
Age, years, mean (SD) 68.1 (9.1)
Current smokers, no. (%) 11 (9.2)
Smoking, pack-years, 
mean (SD)
40 (21.1)
Cardiovascular morbidity, 
no. (%)
36 (29.7)
Exacerbations in the previous 
year, mean (SD)
1.3 (0.5)
Requiring hospital 
admission
0.3 (0.5)
Post-bronchodilator 
spirometry, mean (SD)
FVC, mL 2790 (942)
FVC, % 68.9 (19.2)
FEV1, mL 1406 (493)
FEV1, % 46.4 (14.1)
Table 2: Potentially Pathogenic Microorganisms (PPMs) 
isolated in colonised COPD patients.
No. (%)
Microorganisms isolated
Haemophilus influenzae 21 (42)
Haemophilus 
parainfluenzae
15 (30)
Pseudomonas 
aeruginosa
5 (10)
Streptococcus 
pneumoniae
4 (8)
Moraxella catarrhalis 4 (8)
Staphylococcus aureus 1 (2)
Mixed colonisations (from 
the above microorganisms)
H. influenzae + S. 
pneumoniae
1
H. influenzae + P. 
aeruginosa
3
H. influenzae + H. 
parainfluenzae
2
P. aeruginosa + S. 
viridans
2Miravitlles et al. Respiratory Research 2010, 11:58
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Table 3: Differences between stable COPD patients with and without bacterial colonisation
Variables Colonised (n = 58) Not colonised (n = 61) P value
Sex, men, no. (%) 54 (93.1) 55 (90.2) 0.74
Age, years, mean (SD) 68.3 (8.3) 67.6 (9.8) 0.67
Current smokers, no. (%) 7 (12.1) 4 (6.6) 0.35
Smoking, pack-years, mean (SD) 46.7 (25.1) 34.2 (23.4) 0.006
Cardiovascular morbidity, no. (%) 22 (37.9) 20 (32.8) 0.23
Comorbid conditions, mean (SD) 1.06 (0.99) 0.61 (1.02) 0.025
Use of inhaled steroids, no. (%) 46 (79.3) 47 (77.1) 0.83
Symptoms, no. (%)
Dyspnoea 56 (96.5) 58 (95.1) 0.72
Cough 44 (75.9) 56 (91.8) 0.024
Expectoration 57 (98.3) 58 (95.1) 0.62
Grade of dyspnoea, mean (SD) 1.78 (0.92) 1.15 (0.54) <0.001
Exacerbations in the previous year, no. (%)
Number 0.021
≤2 31 (53.4) 47 (77.1)
>2 27 (46.6) 14 (22.9)
Requiring hospital admission 0.007
None 36 (62.1) 51 (83.6)
≤1 16 (27.6) 10 (16.4)
>1 6 (10.3) 0
Lung function tests, mean (SD)
FVC, mL 2852.7 (979.1) 2710.9 (911.5) 0.41
FVC, % 70.5 (19.5) 66.7 (18.9) 0.28
FEV1, mL 1411.4 (511.7) 1380.0 (433.1) 0.72
FEV1, % 47.4 (15.2) 45.1 (13.1) 0.38
FEV1/FVC 50.4 (11.8) 52.6 (13.9) 0.43
Sputum analysis
Colour, mean (SD) 2.94 (1.0) 1.56 (0.8) <0.001
Pro-inflammatory cytokines, median 
(IQR) in pg/mL
IL-1, n = 53 14 (4-432) 168 (49-758) 0.82
IL-6, n = 53 258 (76-653) 112 (33-368) 0.62
IL-8, n = 61 13480 (1335-43400) 5390 (252-14335) 0.27
TNF-alpha, n = 54 45 (20-94) 35 (10-183) 0.12
FVC = forced vital capacity; FEV1 = forced expiratory volume in the first second; IQR = interquartile range; IL= interleukin; TNF = tumour 
necrosis factor.
patients (Table 4). Sufficient sputum for inflammatory
analysis was available from only 61 subjects, all from
spontaneous sputum. Sputum concentrations of inflam-
matory markers showed a great inter-individual variabil-
ity and did not follow a normal distribution. There were
no significant differences in sputum concentrations for
any of the inflammatory markers analysed between
patients with or without bacterial colonisation (Table 3).
The lack of significance persisted when patients with high
bacterial load were compared with those with low bacte-
rial load and not colonised. However, in this last compar-
ison, patients with high bacterial load presented
consistently (but not significantly) higher concentrations
of all pro-inflammatory cytokines except IL-6 (Table 4).Miravitlles et al. Respiratory Research 2010, 11:58
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The results of the multivariate analysis were very simi-
lar when identifying the factors significantly associated
with the presence of PPMs or on classifying the popula-
tion according to bacterial load. In both cases, only the
degree of dyspnoea and sputum colour were significantly
and independently associated with the presence of PPMs
and with high bacterial load. Sputum colour was a stron-
ger indicator of the presence of positive cultures for
PPMs than its load (Table 5).
Discussion
In the present study, bacterial colonisation of the airways
by PPMs, mainly H. influenzae and H. parainfluenzae,
was reported in 49% of patients with stable COPD. This
finding adds evidence to a high prevalence of bacterial
colonisation of airways in stable COPD reported by oth-
ers [4,5,9-12]. Interestingly, our results using sputum
samples are quite similar to those obtained in other stud-
ies with the use of the PSB technique or bronchial lavage
for microbiologic assessment of the lower airways in
COPD [4,5,11,12,20,21]. The possibility of sputum collec-
tion along a maximum of three monthly clinical visits and
the use of the induced sputum technique in selected cases
may have accounted for this high diagnostic yield of the
sputum. However, most of our patients were able to pro-
duce a valid sputum sample for microbiological examina-
tion and induction of sputum was necessary in only 5
cases. A previous study by our group demonstrated that
spontaneous and induced sputum yielded equivalent
results in terms of frequency of bacterial colonisation and
species recovered [22]. A pooled analysis of data from
studies that used PSB demonstrated that a PPM load ≥102
CFU/mL should be considered abnormal and allowed the
estimation that at least one quarter of the patients with
stable COPD were colonised by PPMs [5]. Furthermore,
most patients with exacerbated COPD had concentration
of PPMs > 105 [4,5]. Since there is no universally accepted
cut-off for high bacterial load in sputum samples, a 105
CFU/mL concentration was used in our study [4,8]. With
this value, 30% of our total population and almost two
thirds of the colonised patients in our study had a high
PPM load.
Bacterial colonisation in our study was related to cumu-
lative consumption of cigarette smoking, history of exac-
erbations in the previous year and sputum colour.
Exacerbations in the previous year leading to hospitalisa-
tion were associated with increased bacterial load,
although this relationship disappeared on multivariate
analysis. In other studies, current smoking and severe air-
flow obstruction have been identified as predisposing
factors for bacterial colonisation in stable COPD [11,12].
However, we did not observe significant differences in
lung function between colonised and non-colonised
patients. The relationship between lung function and fre-
quency of colonisation is not clear, since a lack of associa-
tion between FEV1  and colonisation has also been
observed in other studies [8,12,21,23] and may be due, at
least in part, to the under-representation of mild patients
in most series as well as in the current study. Interest-
ingly, the only two factors identified in multivariate analy-
sis to be significantly and independently associated with
both presence of bacterial colonisation and high bacterial
load were a more severe degree of dyspnoea and a darker
colour of sputum. The degree of dyspnoea is a marker of
severity of COPD and being a categorical variable with a
wider distribution in our population probably contrib-
uted to its demonstrated association with colonisation, in
contrast to the severity of FEV1 impairment.
Regarding bronchial inflammation, it should be noted
that we did not find increased sputum concentrations of
pro-inflammatory cytokines in patients with bacterial
colonisation. Different reasons may explain this finding,
including a small number of patients with valid samples
for analysis, the inter-individual variability in the sputum
concentrations of the cytokines was very large [24], and
there was a large number of patients with low bacterial
loads. In fact, Hill et al. [8] have demonstrated that mark-
ers of inflammation increased progressively with increas-
ing bacterial load in patients with stable COPD.
Consequently, when our colonised patients were catego-
rized according to high or low bacterial load, besides the
persistence of the clinical differences already observed
between the colonised and non-colonised groups (i.e.,
cigarette smoking, hospitalisations in the previous year,
grade of dyspnoea and sputum colour) a non-significant
trend towards higher sputum concentrations of inflam-
matory markers (except IL-6) was observed in patients
with high bacterial load. Our results concur with previ-
ous observations regarding the lack of association
Figure 1 Percentage of bacterial colonisation according to spu-
tum colour (differences statistically significant at P < 0.001).
colour 1= white; 2= light yellow; 3= dark yellow; 4= light green; 5= greenishMiravitlles et al. Respiratory Research 2010, 11:58
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Table 4: Differences between colonised and non-colonised COPD patients according to bacterial load
Variables High bacterial load (≥105) 
(n = 36)
Low bacterial load (<105) 
and not colonised (n = 83)
P value
Sex, men, no. (%) 33 (91.7) 76 (91.6) 0.98
Age, years, mean (SD) 68.6 (6.9) 67.7 (9.9) 0.63
Current smokers, no. (%) 6 (16.7) 5 (6) 0.086
Smoking, pack-years, 
mean (SD)
48.5 (22.5) 36.7 (25.2) 0.017
Cardiovascular morbidity, 
no. (%)
11 (30.6) 31 (37.3) 0.34
Comorbid conditions, 
mean (SD)
0.86 (0.99) 0.83 (1.02) 0.88
Use of inhaled steroids, no (%) 29 (80.6) 64 (77.1) 0.81
Symptoms, no. (%)
Dyspnoea 36 (100) 78 (93.9) 0.66
Cough 25 (69.4) 75 (90.4) 0.007
Expectoration 36 (100) 79 (95.2) 0.31
Grade of dyspnoea, mean (SD) 1.86 (0.83) 1.28 (0.73) <0.001
Exacerbations in the 
previous year, no. (%)
Number 0.32
≤2 20 (55.6) 58 (69.9)
>2 16 (44.4) 25 (30.1)
Requiring hospital 
admission
0.003
None 20 (55.6) 67 (80.7)
≤1 11 (30.6) 15 (18.1)
>1 5 (13.9) 1 (1.2)
Lung function tests, mean 
(SD)
FVC, mL 2936.9 (975.7) 2712 (927.6) 0.23
FVC, % 71.9 (21.0) 67.1 (18.4) 0.21
FEV1, mL 1423.9 (536.5) 1382 (443.1) 0.66
FEV1, % 47.3 (15.9) 45.8 (13.4) 0.61
FEV1/FVC 48.9 (11.2) 52.7 (13.5) 0.15
Sputum analysis
Colour, mean (SD) 2.97 (0.94) 2.01 (1.08) <0.001
Pro-inflammatory 
cytokines, median (IQR) 
in pg/mL
IL-1, n = 53 47 (5-593) 29 (4-255) 0.14
IL-6, n = 53 134 (39-381) 169 (34-415) 0.18
IL-8, n = 61 8060 (460-31400) 4890 (201-15025) 0.09
TNF-alpha, n = 54 76 (11-269) 38 (11-71) 0.96
FVC = forced vital capacity; FEV1 = forced expiratory volume in the first second; IQR = interquartile range; IL= interleukin; TNF = tumour 
necrosis factor.Miravitlles et al. Respiratory Research 2010, 11:58
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between colonisation and increased IL-6 [9,10] but are
discordant with other works showing significantly
increased bronchial IL-8 and TNF-alpha in colonised
patients, particularly with H.influenzae  [9,10,21,23,25].
Therefore, our data, if confirmed in a larger sample of
patients, would also suggest a dose-response relationship
between bacterial load and bronchial inflammation and
that a threshold of bacterial load might be necessary to
elicit a significant inflammatory reaction in the airways
[5,6,26]. In contrast, Sehti et al. [27] examined whether
the increase in bacterial concentrations functions as a
separate mechanism of exacerbation induction, indepen-
dent of a new strain acquisition. In a prospective longitu-
dinal cohort of COPD patients assessed during
exacerbations and stable disease, sputum concentrations
of pre-existing strains of H. influenzae and H. haemolyti-
cus were not significantly different in exacerbation versus
stable disease. Concentrations of M. catarrhalis and S.
pneumoniae were even lower during exacerbations com-
pared with stable periods. However, concentrations of
new strains of H. influenzae and  M. catarrhalis were
increased during exacerbations, but the differences were
small. These authors speculate that change in bacterial
load was unlikely to be a major primary mechanism of
exacerbation induction in COPD [27,28]. This hypothesis
is a matter of debate, because the interpretation of what a
significant increase in bacterial load is when measured in
a logarithmic scale is not clear [10], and when trans-
formed to a non-logarithmic scale, the differences in
absolute bacterial counts were of a very high magnitude
[29].
The identification of bronchial colonisation has clinical
implications. Patel et al. [9] demonstrated that the pres-
ence of lower airway bacterial colonisation in stable
COPD was significantly related to exacerbation fre-
quency and severity. In the study of Rosell et al. [5], again
high bacterial loads were associated with exacerbation
and showed a statistically significant dose-response rela-
tionship between bacterial load and exacerbation after
adjustment for covariates. In our study colonised patients
had significantly more exacerbations and hospital admis-
sions the year previous to the study compared with non-
colonised patients, but the significance disappeared on
multivariate analysis. It should be taken into account that
our study was neither designed nor powered to demon-
strate differences in exacerbation or hospitalisation rates
between colonised and non-colonised COPD patients.
Therefore, the identification of patients colonised by
PPMs using a non-invasive and relatively inexpensive
t ec hni que  s uc h as t he  a nal ys is  of  s put u m  ma y  pla y a n
important role in the management of severe and very
severe COPD, particularly if intervention studies with
antibiotics demonstrate improved clinical outcomes [13].
To facilitate the diagnosis of bronchial colonisation the
use of a surrogate marker could be of interest. Purulence
(colour) of sputum graded by the investigator with a sim-
ple scale from 1 to 5 revealed significant differences in
colour between colonised and non-colonised patients.
Patients with colour 3 or higher (dark yellow to green
sputum) had a prevalence of bacterial colonisation
greater than 80%. The relevance of sputum colour has
been already described and validated for exacerbated
patients in which yellowish or greenish sputum is signifi-
cantly associated with a bacterial exacerbation compared
with white (non-bacterial) sputum [30,31] but the rela-
tionship between sputum colour and bacterial colonisa-
tion in stable COPD has deserved little attention [8].
The present results should be interpreted taking into
account some limitations of the study, particularly the
small sample size may not have allowed determination of
sputum concentrations of inflammatory markers in all
samples, in most cases due to the small recovery of spu-
tum that did not provide enough supernatant for the
quantification of inflammatory mediators. The cross-sec-
tional design did not allow the dynamics and time course
of bacterial colonisation and airway inflammation during
exacerbations to be examined. Patients with negative
bronchodilator test were included to exclude individuals
with asthma who are less likely to be colonised, but the
results may not be extrapolated to partially reversible
COPD patients. High concentrations of PPMs in sputum
samples, however, is a simple parameter that may help to
Table 5: Results of multivariate analysis of factors associated with presence of bacteria in sputum and with high bacterial 
load.
Factor OR 95% CI P value
Factors associated with bacteria in sputum
Degree of dyspnoea 2.63 1.53 - 5.09 0.004
Sputum colour 4.11 2.30 - 7.29 <0.001
Factors associated with high bacterial load as opposed to no bacteria and low bacterial load
Degree of dyspnoea 2.01 1.17 - 3.46 0.012
Sputum colour 1.99 1.32 - 2.99 0.001Miravitlles et al. Respiratory Research 2010, 11:58
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select candidates to participate in antibiotic trials of sta-
ble COPD in order to demonstrate bacterial eradication
and potentially prolong time to exacerbation [6,32,33].
Conclusions
Almost half of a population of ambulatory moderate to
very severe COPD patients carry PPMs in their airways.
Colonised patients had more severe dyspnoea, and spu-
tum colour allows the identification of patients most
likely to be colonised by PPMs.
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